Lv11
20 积分 2022-10-16 加入
A nationwide validation of the prognostic impact of pathological response and the distribution of recurrence patterns in responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma
2小时前
待确认
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer
3小时前
已完结
The patterns and risk factors of relapse in oesophageal squamous cell cancers who achieve pathologic complete response to neoadjuvant chemoradiotherapy
5个月前
已完结
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
5个月前
已完结
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
5个月前
已完结
Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study
5个月前
已完结
Three-Field Versus Two-Field Lymphadenectomy in Minimally Invasive Esophagectomy: 3-Year Survival Outcomes of a Randomized Trial
5个月前
已完结
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma
5个月前
已完结
A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma
5个月前
已完结
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
5个月前
已完结
皖公网安备34019202002308
